Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132821) titled 'A Randomized, Controlled, Open-Label, Multicenter Clinical Trial Comparing Anti-HER2 Therapy Combined with Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer with High HER2 Expression' on Sept. 18.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The First Affiliated Hospital of Air Force Medical University

Condition: Stage IB-II Gastric Cancer

Intervention: Control Group:1. Monotherapy with tegafur for stage IB gastric cancer: Tegafur 40-60 mg (based on body surface area), taken orally twice daily on days 1-14. One cycle consist...